Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Martek Biosciences---- future biotech cash cow! -- Ignore unavailable to you. Want to Upgrade?

To: Machaon who wrote (118)	1/6/1998 11:19:00 PM
From: Dr. Id	Respond to of 258

I hope that they do add this stuff to their products soon... I want this to be a $200 stock to make up for my other biotech losses! (Is that asking too much? :-) ) JB Kidding aside, I do think this stock shows tremendous potential...

To: Machaon who wrote (118)	1/7/1998 2:37:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 258

I agree, all published data indicates that DHA should be in formula. However, if you walk into any GNC, you'll see the MATK product together with others. As a matter of fact, the MATK product was the second to hit the shelves at GNC, and I've seen at least one report of another algae-derived DHA. It appears that MATK doesn't have a lock on patents that exclude competitors from the nutriceutical market? So...... what's to stop competitors from making this a commodity product? Can someone please summarize the patent status for us? Good product, lousy business plan? Thanks, Rick